In a controversial move, Merck is rolling back its commitment to provide a life-saving rotavirus vaccine to parts of West Africa at the same time the drug maker is ramping up supplies to China, where the product would reportedly be sold for a much higher price.

The company supplies its RotaTeq vaccine through an arrangement with GAVI, the Vaccine Alliance, a public-private partnership that helps provide medicines and vaccines to low-income countries. However, Merck is reducing shipments by one-third this year and next, according to GAVI. After that, supplies are not expected. About 4.7 million doses will be delivered this year and 4 million next year.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy